Each of the four key elements mentioned contribute to successful new product planning. As the examples of the obesity, postpartum depression, and immuno-oncology markets show, failing to properly address even one of the key elements risks asset failure.
Engaging seasoned internal resources or an experienced external partner enables new product planning teams to develop a comprehensive plan, identify quality analogs for additional insights, and ensure smooth execution. At Herspiegel Consulting, we have worked with many clients of varying sizes across a number of therapeutic areas to establish new product planning strategy through execution.
For more information or to discuss how we can help with new product planning, please contact Beth Schurman at email@example.com
Alternatively, you may fill out the form below and we'll be in touch
1. LaMattina, J. (2016, December 16). Gilead's CEO Admits To 'Failures' In Setting Price of $1,000-A-Pill Breakthrough. Retrieved from https://www.forbes.com/sites/johnlamattina/2016/12/08/gileads-ceo-apologetic-about-sovaldis-1000-per-pill-price-tag/#2755ac9f1a97
2. J Health Biomed Law. Author manuscript; available in PMC 2018 Sep 24. Published in final edited form as: J Health Biomed Law. 2018 Sep; 14: 265–2833.
3. Amgen cuts price of PCSK9 inhibitor by 60%. (2019, January 23). Retrieved from https://www.cardiovascularbusiness.com/topics/healthcare-economics/amgen-cuts-price-pcsk9-inhibitor-604.
4. Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis. (n.d.). Retrieved from https://www.novartis.com/news/media-releases/novartis-and-pear-therapeutics-develop-digital-therapeutics-patients-schizophrenia-and-multiple-sclerosis
5. Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder. (n.d.). Retrieved from https://www.novartis.com/news/media-releases/sandoz-and-pear-therapeutics-announce-us-launch-reset-otm-help-treat-opioid-use-disorder
6. Click Therapeutics teams up with Otsuka on digital therapeutic for major depressive disorder. (2019, January 03). Retrieved from https://www.mobihealthnews.com/content/click-therapeutics-teams-otsuka-digital-therapeutic-major-depressive-disorder
7. Brooke, E. (2018, June 08). Can You Build a Lifestyle Brand Around Erectile Dysfunction? Retrieved from https://www.racked.com/2018/6/8/17429442/hims-roman-keeps-ed-hair-loss-startups-branding
8. Telemedicine for Obesity - The Future of Weight Loss is Here. (2019, February 24). Retrieved from https://www.globalmed.com/telemedicine-is-the-future-of-obesity-treatment/
9. Medications for the Treatment of Psychiatric & Mood Disorders. (n.d.). Retrieved from https://www.sagerx.com/programs-research/psychiatric-disorders/
10. Globaldata Catalyst Monitor March 2019
11. Valeritas Reports Record Revenue for the Third Quarter 2018. (n.d.). Retrieved from https://www.valeritas.com/investors/press-releases/press-release-details/2018/Valeritas-Reports-Record-Revenue-for-the-Third-Quarter-2018/default.aspx
12. Globaldata. To Market, To Market, To Buy a Weight Management Therapy. Publication Date: June 2013
13. Young, A., Merie, E., & Hesser, G. (n.d.). It's More than Just an IO Play to Us. Retrieved from https://research-doc.credit-suisse.com.
14. Prendergast, G. C., Malachowski, W. P., DuHadaway, J. B., & Muller, A. J. (2017, December 15). Discovery of IDO1 Inhibitors: From Bench to Bedside. Retrieved from http://cancerres.aacrjournals.org/content/77/24/6795
15. Pagliarulo, N. (2017, June 03). ASCO17: Incyte pads its IDO numbers. Retrieved from https://www.biopharmadive.com/news/asco-incyte-ido-epacadostat-market-value/444151/
16. Event – A defining moment for IDO inhibition. (2018, July 11). Retrieved from http://www.evaluate.com/vantage/articles/analysis/event-defining-moment-ido-inhibition